BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held company that develops cloud-based software offerings for advanced medication management.
This acquisition expands the company’s medication management offerings into the care continuum space and provides deeper integration with electronic health records (EHRs).
“This strategic acquisition brings together our industry leading BD Pyxis™ Automated Dispensing Cabinets with the Medical Business of CUBEX’s MedBank cloud-based software and analytics platform to help enable patient centered care beyond the acute care setting,” said Mike Garrison, worldwide president of Medication Management Solutions at BD. “We are committed to improving and connecting the medication management process across health care settings, and this acquisition allows us to help address the unique needs care continuum facilities face, from minimizing medication diversion to improving inventory management.”
The Medical Business of CUBEX’s key offering is a cloud-based software that supports decentralized medication management and provides unique features specialized for pharmacists and nurses across the care continuum. BD previously worked under a commercial distribution relationship with CUBEX.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“The Medical Business of CUBEX prides itself on developing software and analytics for advanced medication management that focus on the needs of the pharmacist and nurse to help alleviate administrative burden while ensuring patient safety,” said Anton Visser, CUBEX CEO. “By joining BD – a leading med tech company – we look forward to the expanded impact our solutions will have towards improved patient care.”
BD is excited to welcome approximately 40 CUBEX associates into the BD family. Terms of the transaction were not disclosed. The acquisition does not impact BD’s fiscal 2021 guidance.